Advertisement

Topics

Acorda halts enrollment in Parkinson's trial, shares plunge

02:50 EST 15 Nov 2017 | Reuters

(Reuters) - Acorda Therapeutics Inc's shares plunged 34 percent on Wednesday after the drugmaker said it had paused enrolling patients in two key trials testing its Parkinson's disease drug following patient deaths.

Original Article: Acorda halts enrollment in Parkinson's trial, shares plunge

NEXT ARTICLE

More From BioPortfolio on "Acorda halts enrollment in Parkinson's trial, shares plunge"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Parkinson's Disease
Parkinson's is a progressive neurological condition, affecting one person in every 500, 95% of which are over 40. It is caused by degeneration of more than 70% of the substantia nigra, which depletes the dopamine (the neurotransmitter involved in pro...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...